Swedish Orphan Biovitrum AB (OSTO:SOBI) 5-Year EBITDA Growth Rate : 7.60% (As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Swedish Orphan Biovitrum AB 5-Year EBITDA Growth Rate?

Swedish Orphan Biovitrum AB's EBITDA per Share for the three months ended in Mar. 2024 was kr6.46.

During the past 12 months, Swedish Orphan Biovitrum AB's average EBITDA Per Share Growth Rate was -0.30% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 1.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 7.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 41.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Swedish Orphan Biovitrum AB was 97.90% per year. The lowest was -42.70% per year. And the median was 42.90% per year.

Competitive Comparison of Swedish Orphan Biovitrum AB's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Swedish Orphan Biovitrum AB's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's 5-Year EBITDA Growth Rate falls into.

Swedish Orphan Biovitrum AB 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Swedish Orphan Biovitrum AB (OSTO:SOBI) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Swedish Orphan Biovitrum AB 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB (OSTO:SOBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OSTO:SOBI) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

SWOBY:USA BIOVF:USA SOBIs:UK 0MTD:UK B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (OSTO:SOBI) Headlines

No Headlines